Lv1
12 积分 2021-07-14 加入
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study
2个月前
已完结
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2个月前
已完结
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
3个月前
已完结
Delayed insulin secretion response during an OGTT is associated with an increased risk for incidence of diabetes in NGT subjects
6个月前
已完结
Issues in Using Progression-Free Survival When Evaluating Oncology Products
6个月前
已完结
皖公网安备34019202002308
